


sequenced with the material that was resequenced to obtain the corrected sequence, and (3) clearly show any differences between the originally disclosed sequence and the amended sequence. Entry of the resequenced sequence into the instant application is achieved via integration of Substitute Sequence Listing submitted herewith. Entry of Substitute Sequence Listing, Amendments and revised Figures 1 and 2 that flow therefrom, is respectfully requested.

Applicants respectfully request that the amendments and remarks of the present Second Preliminary Amendment be entered and made of record in the file history of the instant application. Applicants believe that the instant application is in condition for substantive examination. If in the opinion of the Examiner, a telephone conference would expedite prosecution, the undersigned can be reached at the telephone number indicated below. If a fee is required in connection with this paper, please charge Deposit Account No. 08-3425 for the appropriate amount.

Respectfully submitted



Michelle S. Marks (Reg. No. 41,971)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 610-5761 (telephone)

Date: 12/7/99

MSM/mbp